Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Supplementation of a Leucine-Enriched Dairy Protein Blend

6 de febrero de 2020 actualizado por: Stuart Phillips, McMaster University

Supplementation of a Leucine-Enriched Dairy Protein Blend: Effects on Plasma Amino Acids in Older Adults

It is well known that dietary protein is a powerful transient stimulator of the muscle protein synthetic rate (MPS) whereby changes in MPS in response to feeding may be regulated by specific downstream target proteins of mammalian target of rapamycin signaling, such as S6K1, rpS6, and eIF2B. A meal deficient in protein, however, does not increase the rate of MPS because a rise in the bioavailability of amino acids does not occur. In addition, the source of dietary proteins has been shown to impact postprandial blood levels of amino acids. The concept that certain types of proteins are "fast acting" or "slow acting" has been shown to affect the postprandial profile of amino acids appearing in the systemic circulation. Native whey and micellar casein are both dairy proteins that contain a similar amount of essential (EAA), but blood EAA levels increase faster and to a higher level after the consumption of whey protein. Differences in gastric emptying, digestion and absorption kinetics between micellar casein and native whey are the underlying factors. Nonetheless, micellar casein protein has been shown to protract MPS in humans. Despite the significant amount of information gained with respect to both of these protein sources, the effects of combinatorial formulations on the postprandial profile of amino acids appearing in the blood is less well known. The purpose of the present study is to determine post-ingestion aminoacidemia, glycemia, and insulinemia from a specially formulated dairy protein blend.

Descripción general del estudio

Estado

Desconocido

Condiciones

Descripción detallada

Experimental approach:

8 participants will be included in this study. Each participant will consume the supplement only once in a randomized fashion during three separate visits and there will be approximately 1 week between each visit.

Standardized meal:

Participants will be provided a standardized diet one day prior to experimentation. When performing research involving human metabolism it is important that the participants be tested in a weight-stable state. Therefore, the investigators will estimate the participants resting energy expenditure using a widely reference prediction formula, known as the Harris-Benedict equation. This formula takes into account gender, body mass, height, age, and self-reported activity level. Once resting energy expenditure is calculated the investigators will provide each participant with a pre-packaged standardized diet for the day prior to the experiment that is designed to ensure a sufficient energy balance.

Dual Energy X-Ray Absorptiometry (DXA) Scans:

DXA scans will be used to determine the participants body composition. The DXA procedures use a small amount of radiation to determine how much fat, bone, and lean mass the participants have in their body. The procedure takes approximately seven minutes and involves the participants lying still on an open bed while the sensor passes over the participants body.

Arterialized blood sampling:

All blood sampling will be achieved through an intravenous indwelling cannula. This method provides the least trauma to the participant when repeated blood sampling is required and is convenient for the investigators. In theory, repeated needle sticks may stress the participant thereby increasing sympathetic nervous system activity, thus causing changes in metabolism. Additionally, another potential drawback from venous blood sampling is the influence by regional tissue specific metabolism, thereby making it difficult to interpret whole-body metabolism on the basis of metabolites measured in venous blood. Therefore, arterial blood sampling is deemed the ideal method for metabolic studies. Arterial cannulation, however, may be unethical for research purposes due to increased risk of complications, such as damage to the arterial wall, thrombosis, and clot formation, all of which may cause death. Arterializing the blood being sampled can be achieved through heating either the superficial antecubital vein or dorsal hand vein with a heating blanket or specialized heat box. By doing so, blood flow increases as a result of vasodilatation of vessels in the arms skeletal musculature, as well as arteriovenous anastomoses in skin. Due to the increased blood flow and negligible muscle mass at the hand and elbow, results in venous blood being similar in composition to an arterial sample. This method is a widely used surrogate for safe direct arterial blood sampling. Once arterialized blood samples are obtained they will be preserved and used in analyses. The investigators will utilize heating blankets (Theratherm Large Digital Moist Heat Pad [14" x 27"]) to arterialize the blood samples and an infrared thermometer (Nubee, NUB8380) to determine the skin temperature (45-68∘C) prior to drawing the participant's blood.

Per-protocol conditions will include:

Consumption of a standardized meal the evening prior to each trial and consistent exercise/activity 2d before each trial There will be ~1wk between trials (washout periods) Blood samples will be analyzed for plasma amino acids, glucose, and insulin.

Experimental Interventions (randomized order):

  1. Participants will consume a Low Protein Containing Breakfast (10% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine) and 2 hours later the participants will consume 17g of a leucine enriched whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein) containing 600 IU Vitamin D and 3.5g leucine
  2. Participants will consume a High Protein Containing Breakfast (25% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine)
  3. Participants will consume a Low Protein Containing Breakfast (10% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine)

Proteins were provided by Covance Laboratories, Inc. owned by Eurofins.

The whey protein and micellar casein are milk proteins derived from cow's milk. The participants will consume the 17g of protein contained in a semi-solid bar equal to ∼40g, which is the size of a typical sports recovery bar.

Sample size and data analyses:

The sample size was determined by a statistical power analysis (G*Power 3.1 software, version 3.1.9, 2014) that revealed a large effect size. This study was powered on the basis of previous studies. Thus, a total of 8 (n = 8/group) participants will be used in analyses. See Below:

Analysis: A priori: Compute required sample size ANOVA: Repeated measures, within-between interaction Input Effect size f = 0.5 α err prob = 0.05 Power (1-β err prob) = 0.95 Number of groups = 3 Number of measurements = 14 Corr. Among rep. measures = 0.5 Nonsphericity correction ε = 1 Output Noncentrality parameter ƛ = 63 Critical F = 1.6380186 Numerator df = 26 Denominator df = 78 Total sample = 9 Actual power = 0.997

Tipo de estudio

De observación

Inscripción (Actual)

8

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ontario
      • Hamilton, Ontario, Canadá, L8S 4K1
        • Exercise Metabolism Research Laboratory, McMaster Univeristy

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

65 años y mayores (Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Healthy Older Adults

Descripción

Inclusion Criteria:

  • 8 participants will be included in this study. Each participant will consume the supplement only once in a randomized fashion during one of three separate visits and there will be approximately 1 week between each visit. In order to participate in this study, each participant must be male or female, 65 years or older (inclusive) and cannot be a smoker or user of tobacco products.

Exclusion Criteria:

  • The exclusion requirements for this study include the following conditions:

    • Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded. However, a washout period of 4 weeks will be suitable for participation.
    • A history of neuromuscular problems or muscle and/or bone wasting diseases
    • Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
    • Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Supplementation with Enriched Protein®
Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
This product contains high quality bovine milk proteins enriched with additional leucine.
Low protein breakfast
No supplementation
High protein breakfast
No supplementation

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Easy-fast amino acid sample testing kit for gas chromatography mass spectrometry
Periodo de tiempo: 375 minutes
plasma amino acid concentrations
375 minutes

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hexokinase/G-6-PDH methodology
Periodo de tiempo: 375 minutes
plasma glucose concentrations
375 minutes
Chemiluminescent Microparticle Immunoassay
Periodo de tiempo: 375 minutes
plasma insulin concentrations
375 minutes
Visual Analog Scale Questionnaires for food sensory perception desire to eat
Periodo de tiempo: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for hunger
Periodo de tiempo: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for fullness
Periodo de tiempo: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for thirst
Periodo de tiempo: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for how much food could be eaten
Periodo de tiempo: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for liking or disliking of food
Periodo de tiempo: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for visual appeal
Periodo de tiempo: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for smell
Periodo de tiempo: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for taste
Periodo de tiempo: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for aftertaste
Periodo de tiempo: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for pleasantness
Periodo de tiempo: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Height in meters
Periodo de tiempo: One measurement at baseline
Stadiometer
One measurement at baseline
Weight in kilograms
Periodo de tiempo: One measurement at baseline
Physician scale
One measurement at baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de marzo de 2018

Finalización primaria (Actual)

1 de diciembre de 2019

Finalización del estudio (Anticipado)

1 de junio de 2020

Fechas de registro del estudio

Enviado por primera vez

16 de octubre de 2018

Primero enviado que cumplió con los criterios de control de calidad

18 de octubre de 2018

Publicado por primera vez (Actual)

19 de octubre de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

7 de febrero de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

6 de febrero de 2020

Última verificación

1 de febrero de 2020

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2502

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Enriched Protein®

3
Suscribir